Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 366 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ribavirin (RBV) Clear all
Terminated Phase 4 Interventional

Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin

NCT00194857
View directory record Official record
Conditions
Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
Interventions
erythropoietin, GCSF
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Early Phase 1 Interventional

Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation

NCT01909401
View directory record Official record
Conditions
Liver Transplantation
Interventions
boceprevir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

NCT02094443
View directory record Official record
Conditions
Hepatitis C, Liver Disease
Interventions
Alisporivir, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Bakersfield, California • Lancaster, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

NCT00502788
View directory record Official record
Conditions
Hepatitis C, Thalassemia
Interventions
Peginterferon Alfa-2a and Ribavirin, Ribavirin
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 44 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Oakland, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

NCT01485991
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, TVR
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
32
States / cities
Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

NCT01215643
View directory record Official record
Conditions
Hepatitis C, Chronic Pain
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Ventura, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

NCT02249182
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

NCT02781649
View directory record Official record
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 1 Interventional

A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems

NCT00001015
View directory record Official record
Conditions
HIV Infections
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 2:00 AM EDT
Terminated Phase 4 Interventional Results available

Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

NCT02717949
View directory record Official record
Conditions
Liver Disease
Interventions
sofosbuvir/ledipasvir, sofosbuvir, Ribavirin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy

NCT01405027
View directory record Official record
Conditions
Chronic Hepatitis C, Genotype 1
Interventions
Educational Intervention, Patient education and management skills training
Procedure · Other
Lead sponsor
Chronic Liver Disease Foundation
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
43
States / cities
Beverly Hills, California • Calabasas, California • Santa Monica, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

Ph IIA Study (SOC +/- NS5B)

NCT01193361
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 4 Interventional

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

NCT00575224
View directory record Official record
Conditions
Chronic Hepatitis C, Asian Americans, Novel Genotypes, Treatment
Interventions
Pegylated interferon and ribavirin
Drug
Lead sponsor
Pacific Health Foundation
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
San Diego, California • San Jose, California • Westminster, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Not applicable Interventional

A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome

NCT00001123
View directory record Official record
Conditions
Hantavirus Pulmonary Syndrome
Interventions
Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PSI-7977, Daclatasvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Coronado, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 4 Interventional Results available

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

NCT00107653
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
58
States / cities
Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

NCT03724149
View directory record Official record
Conditions
Lung Diseases
Interventions
Zepatier, Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 67 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 7, 2026, 2:00 AM EDT
Terminated Phase 4 Interventional

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

NCT00456248
View directory record Official record
Conditions
Hepatitis C
Interventions
Infergen and ribavirin
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Atlanta, Georgia • New Orleans, Louisiana • Harrisburg, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

NCT02113631
View directory record Official record
Conditions
Hepatitis C, Chronic, Cirrhosis
Interventions
Telaprevir, Boceprevir, Peg-IFN, Ribavirin
Drug
Lead sponsor
Louis Stokes VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

NCT01389323
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
35
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 3 Interventional

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

NCT01573351
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 7, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

NCT02175966
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 7, 2026, 2:00 AM EDT